ANXA1 and stroke disorder: In conclusion, we provide strong supporting evidence that AnxA1 mimetic peptide AnxA1Ac2-26 possesses an arsenal of immune responses extending beyond that of an anti-inflammatory (e.g., attenuation of leukocyte-platelet responses post stroke, reduction of lipopolysaccharide-induced leukocyte adhesion and migration) and pro-resolution mediator to also include a role as an anti-coagulant and anti-thrombotic agent.